ASs have also been demonstrated to increase glucagon-like-peptide-1 (GLP-1), which has been observed to reduce motility in the antro-duodeno-jejunal area and suppress the migrating motility complex in both individuals without any gastrointestinal disorders and those diagnosed with irritable bowel syndrome, and peptide YY (PYY), which can induce a delay in intestinal transit [35-39]. Here, GCG is linked to digestive system disorder.